We used a similar approach in order to evaluate the combination of T-DM1 with VSVΔ51 in a murine model of HER2+ cancer, where JIMT1 trastuzumab-resistant human breast cancer xenografts were implanted subcutaneously into nude mice and allowed to grow to ~100 mm3. This evidence concerns the gene ERBB2 and breast carcinoma.